Overprescription of short-acting β 2 -agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study.

SABA overprescription occurred in almost half of all patients in the Middle East, underscoring the need for healthcare providers and policymakers to adhere to the latest evidence-based recommendations to address this public health concern.